(Q36094059)

English

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial (English)

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

phase III clinical trial

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

William Stohl

1

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Juan Gomez-Reino

2

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ewa Olech

3

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jean Dudler

4

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Roy M Fleischmann

5

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Cristiano A F Zerbini

6

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Ali Ashrafzadeh

7

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Susanna Grzeschik

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Rebecca Bieraugel

9

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Jennifer Green

10

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Steven Francom

11

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Wolfgang Dummer

12

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

language of work or name

0 references

publication date

2 February 2012

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

71

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

8

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

1289-1296

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396459

2 October 2017

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396459

2 October 2017

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396459

2 October 2017

The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396459

2 October 2017

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396459

23 September 2018

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3396459

23 September 2018

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

https://pubmed.ncbi.nlm.nih.gov/22307942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22307942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III

1 reference

https://pubmed.ncbi.nlm.nih.gov/22307942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22307942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/22307942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/22307942

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2011-200706

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36094059&oldid=1617299108"